Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine and sulfasalazine combination regimens for active rheumatoid arthritis
ChiCTR2100043373Phase 4Completed
- Sponsor
- Renji Hospital
- Start
- Jul 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of hydroxychloroquine, 5-aminosalicylic acid + sulphasalazine and methotrexate in rheumatoid arthritis (RA) (4 arms), sponsored by Renji Hospital. Primary endpoints: ACR20, ACR50 and 4 more. Started Jul 2009; status: completed.
02
Drugs
hydroxychloroquine5-aminosalicylic acid + sulphasalazinemethotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2100043373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043373.